Antibody Efficacy-enhanced Engineering Service

Background of Antibody Efficacy-enhanced Engineering

Therapeutic antibodies have become a rapidly developing industry in recent years, and occupy an important position in the field of anti-tumor and autoimmune treatment. In the applications of therapeutic antibodies, the conventionally developed antibodies often can't achieve excellent results, and usually need to be modified in terms of affinity, immunogenicity, and half-life to improve the specificity and potency of antibodies, reduce the dose of drugs, as well as reduce the side effects. Accordingly, Creative Biolabs delivers a cost-effective antibody efficacy-enhanced engineering service to advance the applications of therapeutic antibodies in clinical.

Fig. 1 The evolution of Fc-engineered therapeutic antibodies marks a new era in antibody treatment modalities.¹

Our Antibody Efficacy-enhanced Engineering Service

Enhancing the efficacy of antibodies is extremely important for therapeutic use. Creative Biolabs' antibody efficacy-enhanced engineering service has the potential to be an effective research tool for therapeutic antibody optimization in efficacy. Our efficacy-enhanced strategies include antibody affinity maturation and antibody specificity optimization. Our scientists are willing to help global customers design the optimal project plans to discover and develop antibodies with greatly increased efficacy. In addition, we deliver a series of well-equip engineering approaches to perform customers' meaningful projects, such as display technologies and computer-aided design. At Creative Biolabs, we specialize in expediting the development and production of antibodies for a variety of applications. Our team offers customized research solutions to meet your unique requirements.

Antibody Affinity Maturation

The affinity of a therapeutic antibody for antigens is critical for its effectiveness in targeted therapy. Therefore, one of our antibody efficacy-enhanced strategies is to improve antibodies' affinity and promote the binding interactions to target antigens. We provide a set of methods including random mutagenesis, targeted mutagenesis, chain shuffling, in silico approaches, etc.

Antibody Specificity Optimization

For this strategy, we offer Fc engineering service to enhance the interaction between antibodies and immune cells. Specifically, we take advantage of mutagenesis technology (Random mutagenesis and targeted mutagenesis) to obtain distinctive Fc variants. Furthermore, we provide an innovative approach in silico design of antibodies with mapped epitopes to optimize antibodies' specificity.

The binding of FcγRs to the glycosylated portions of the CH2 domains is influenced by the glycan composition at those sites, affecting the strength of Fc effector functions. Therefore, we also deliver glycosyl modification service on the antibody Fc domains for improving Fc and FcγR interaction.

Benefits for You

Ph.D. Research Team.
Multiple Engineering Selection.
Fast Timelines.
One-stop Customized Service.

Case Study

The study outlines the advancement and assessment of Fc-optimized anti-SARS-CoV-2 monoclonal antibodies (mAbs) with increased potency for the prevention and treatment of COVID-19. By targeting activating Fcγ receptors, Fc variants designed for FcγRIIa (GA) or FcγRIII (ALIE) demonstrate enhanced therapeutic effectiveness compared to standard IgG1. Particularly, the GAALIE variant, optimized for both FcγRIIa and FcγRIII with reduced affinity for inhibitory FcγRIIb, exhibits the highest therapeutic activity. These results can guide the development of Fc-engineered mAbs with superior Fc effector function, offering a more effective clinical approach against COVID-19.

Fig. 2 Engaging activating FcγRs enhances antiSARS-CoV-2 mAbs' therapeutic efficacy.²

If you are interested in our antibody efficacy-enhanced engineering service, please feel free to contact us contact us with your challenging projects.

References

Abdeldaim, Dalia T., and Katharina Schindowski. "Fc-engineered therapeutic antibodies: recent advances and future directions." Pharmaceutics 15.10 (2023): 2402.
Yamin, Rachel, et al. "Fc-engineered antibody therapeutics with improved efficacy against COVID-19." Research Square (2021).